PetVivo Holdings Inc

petvivo.com

PetVivo Holdings Inc (NASDAQ: PETV) is a veterinary medical products company that commercializes and licenses biomaterial-based treatments for companion animals. Revenue is generated through product sales of its Spryng® intra-articular injection and through licensing agreements, distributed via agreements with Vedco and Clipper Distributing. The company competes against established pharmaceutical and veterinary treatment options including NSAIDs, steroid injections, and hyaluronic acid injections used to manage osteoarthritis in dogs and horses. Incorporated in March 2009 under Nevada law, PetVivo operates as a single segment from its headquarters in Edina, Minnesota. Its core products are derived from proprietary biomaterials composed of naturally occurring proteins including collagen, elastin, and heparin, originally developed for human biomedical applications and adapted for veterinary use. The company has never paid a cash dividend and has financed operations primarily through equity issuances, including a public offering completed August 13, 2021, that raised approximately $11.3 million in gross proceeds. As of March 31, 2025, there were approximately 258 stockholders of record.